Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer

被引：0

作者：

Spring, L. M. ^{[1
,2
]}

Han, H. ^{[3
]}

Hamilton, E. ^{[4
]}

Irie, H. ^{[5
]}

Santa-Maria, C. A. ^{[6
]}

Reeves, J. ^{[7
]}

Pan, P. ^{[8
]}

Shan, M. ^{[8
]}

Tang, Y. ^{[8
]}

Graham, J. R. ^{[8
]}

Hazard, S. ^{[8
]}

Ellisen, L. W. ^{[1
,2
]}

Isakoff, S. J. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Tampa, FL USA

[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[6] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[7] Sarah Cannon Res Inst, Florida Canc Specialists South, Ft Myers, FL USA

[8] GSK, Waltham, MA USA

来源：

BREAST | 2021年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P095

引用

页码：S55 / S56

页数：2

共 50 条

[1] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Spring, Laura M.
Han, Hyo
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Reeves, James
Pan, Peng
Shan, Ming
Tang, Yongqiang
Graham, Julie R.
Hazard, Sebastien
Ellisen, Leif W.
Isakoff, Steven J.
NATURE CANCER, 2022, 3 (08) : 927 - +
[2] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
Nature Cancer, 2022, 3 : 927 - 931
[3] Pilot neoadjuvant study of niraparib in HER2-negative, BRCA-mutated resectable breast cancer
Han, Hyo
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Reeves, James
Liem, Andre
Naraine, Adrianna Milillo
Nangia, Julie
Page, David
Duncan, Meghan
Shan, Ming
Tang, Yongqiang
Graham, Julie R.
Ellisen, Leif W.
Isakoff, Steven
Spring, Laura
CANCER RESEARCH, 2020, 80 (04)
[4] Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
Nature Cancer, 2022, 3 : 1138 - 1138
[5] Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer
Shan, Ming
Spring, Laura
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Isakoff, Steven J.
Reeves, James
Ellisen, Leif W.
Lim, Lee P.
Garg, Kavita
Bertucci, Caterina
Feng, Bin
Zhang, Hailei
Sun, Kaiming
Graham, Julie R.
Hofstatter, Erin
Han, Hyo
CANCER RESEARCH, 2022, 82 (04)
[6] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Jul, 10.1038/s43018-022-00400-2, 2022)
Spring, Laura M.
Han, Hyo
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Reeves, James
Pan, Peng
Shan, Ming
Tang, Yongqiang
Graham, Julie R.
Hazard, Sebastien
Ellisen, Leif W.
Isakoff, Steven J.
NATURE CANCER, 2022, 3 (09) : 1138 - 1138
[7] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
McCrea, Charles
Hettle, Robert
Gulati, Poonam
Taneja, Ankush
Rajora, Preety
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 1021 - 1030
[8] Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer
Takamizawa, Shigemasa
Ishiki, Hiroto
Shimoi, Tatsunori
Shimizu, Masaki
Satomi, Eriko
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23)
[9] Real-world clinical outcomes of patients with BRCA-mutated (BRCAm) HER2-negative metastatic breast cancer: A CancerLinQ® study
Miller, Robert S.
Mokiou, Stella
Taylor, Aliki
Jiang, Miao
Sun, Ping
McCutcheon, Susan
CANCER RESEARCH, 2021, 81 (04)
[10] ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy
Turner, Nicholas C.
Cescon, David W.
Loibl, Sibylle
Janni, Wolfgang
Rugo, Hope
Balmana, Judith
Crowley, Cheynna
Chung, Jon
Fucli, Giulia
Hofstatter, Erin
Frenkl, Tara
Telli, Melinda L.
CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →